...
immp-img

Immutep Ltd ADR, Common Stock

IMMP

NMQ

$2.08

-$0.1

(-4.59%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$338.25M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
226.24K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.92
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.66 L
$3.33 H
$2.08

About Immutep Ltd ADR, Common Stock

Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. In addition, it develops INSIGHT-003, which is in phase I to treat 1L NSCLC and solid tumors; INSIGHT-005, which is in phase I to treat metastatic urothelial cancer; IMP761, which is in preclinical trial to treat autoimmune disease; and IMP731 and IMP701 which is in clinical development. Further, the company develops LAG525, which is in phase II clinical trial to treat solid tumors and blood cancer, triple negative breast cancer, and melanoma; and in phase I to treat triple negative breast cancer. Immutep has collaboration with Merck & Co., Inc., GlaxoSmithKline, EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameIMMPSectorS&P500
1-Week Return-4.59%-3.72%-0.05%
1-Month Return5.58%-1.85%2.75%
3-Month Return-9.96%-11.4%7.4%
6-Month Return-22.68%-4.41%10.47%
1-Year Return-11.49%4.13%27.57%
3-Year Return-36.97%0.3%29.56%
5-Year Return23.81%36.62%89.3%
10-Year Return-28.28%106.81%206.09%

Financials

Jun '20Jun '21Jun '22Jun '23Jun '245YR TREND
Total Revenue7.49M3.97M170.37K3.51M3.84M[{"date":"2020-06-30","value":100,"profit":true},{"date":"2021-06-30","value":53,"profit":true},{"date":"2022-06-30","value":2.28,"profit":true},{"date":"2023-06-30","value":46.83,"profit":true},{"date":"2024-06-30","value":51.32,"profit":true}]
Cost of Revenue22.47M2.07M2.06M2.06M41.55M[{"date":"2020-06-30","value":54.09,"profit":true},{"date":"2021-06-30","value":4.98,"profit":true},{"date":"2022-06-30","value":4.97,"profit":true},{"date":"2023-06-30","value":4.96,"profit":true},{"date":"2024-06-30","value":100,"profit":true}]
Gross Profit(14.99M)1.90M(1.89M)1.44M(37.70M)[{"date":"2020-06-30","value":-789.57,"profit":false},{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":-99.74,"profit":false},{"date":"2023-06-30","value":76.07,"profit":true},{"date":"2024-06-30","value":-1986.54,"profit":false}]
Gross Margin(200.18%)47.83%(1111.18%)41.19%(981.42%)[{"date":"2020-06-30","value":-418.51,"profit":false},{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":-2323.11,"profit":false},{"date":"2023-06-30","value":86.11,"profit":true},{"date":"2024-06-30","value":-2051.82,"profit":false}]
Operating Expenses22.56M19.66M34.01M42.88M50.40M[{"date":"2020-06-30","value":44.76,"profit":true},{"date":"2021-06-30","value":39,"profit":true},{"date":"2022-06-30","value":67.48,"profit":true},{"date":"2023-06-30","value":85.07,"profit":true},{"date":"2024-06-30","value":100,"profit":true}]
Operating Income(16.02M)(19.56M)(33.94M)(44.94M)(88.10M)[{"date":"2020-06-30","value":-1601888200,"profit":false},{"date":"2021-06-30","value":-1956057700,"profit":false},{"date":"2022-06-30","value":-3393755400,"profit":false},{"date":"2023-06-30","value":-4493703000,"profit":false},{"date":"2024-06-30","value":-8810418600,"profit":false}]
Total Non-Operating Income/Expense2.74M1.87M1.82M5.96M-[{"date":"2020-06-30","value":45.97,"profit":true},{"date":"2021-06-30","value":31.37,"profit":true},{"date":"2022-06-30","value":30.52,"profit":true},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":"-","profit":true}]
Pre-Tax Income(13.47M)(29.90M)(32.21M)(39.90M)(42.72M)[{"date":"2020-06-30","value":-1346819500,"profit":false},{"date":"2021-06-30","value":-2990259100,"profit":false},{"date":"2022-06-30","value":-3221079200,"profit":false},{"date":"2023-06-30","value":-3989634800,"profit":false},{"date":"2024-06-30","value":-4271662500,"profit":false}]
Income Taxes37.0033.0034.002.002.00[{"date":"2020-06-30","value":100,"profit":true},{"date":"2021-06-30","value":89.19,"profit":true},{"date":"2022-06-30","value":91.89,"profit":true},{"date":"2023-06-30","value":5.41,"profit":true},{"date":"2024-06-30","value":5.41,"profit":true}]
Income After Taxes(13.47M)(29.90M)(32.21M)(39.90M)-[{"date":"2020-06-30","value":-1346823200,"profit":false},{"date":"2021-06-30","value":-2990262400,"profit":false},{"date":"2022-06-30","value":-3221082600,"profit":false},{"date":"2023-06-30","value":-3989635000,"profit":false},{"date":"2024-06-30","value":"-","profit":true}]
Income From Continuous Operations(13.47M)(29.90M)(46.82M)(39.90M)-[{"date":"2020-06-30","value":-1346823200,"profit":false},{"date":"2021-06-30","value":-2990262400,"profit":false},{"date":"2022-06-30","value":-4682423354,"profit":false},{"date":"2023-06-30","value":-3989634800,"profit":false},{"date":"2024-06-30","value":"-","profit":true}]
Income From Discontinued Operations-----[{"date":"2020-06-30","value":"-","profit":true},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}]
Net Income(13.47M)(29.90M)(32.21M)(39.90M)(42.72M)[{"date":"2020-06-30","value":-1346823200,"profit":false},{"date":"2021-06-30","value":-2990262400,"profit":false},{"date":"2022-06-30","value":-3221082600,"profit":false},{"date":"2023-06-30","value":-3989634800,"profit":false},{"date":"2024-06-30","value":-4271662500,"profit":false}]
EPS (Diluted)(0.03)(0.40)-(0.30)-[{"date":"2020-06-30","value":-3.05,"profit":false},{"date":"2021-06-30","value":-40.04,"profit":false},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":-30.26,"profit":false},{"date":"2024-06-30","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

IMMP
Cash Ratio 17.34
Current Ratio 18.25
Quick Ratio 18.07

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

IMMP
ROA (LTM) -16.67%
ROE (LTM) -26.21%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

IMMP
Debt Ratio Lower is generally better. Negative is bad. 0.06
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.94

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

IMMP
Trailing PE NM
Forward PE 7.65
P/S (TTM) 88.04
P/B 2.63
Price/FCF NM
EV/R 803.42
EV/Ebitda NM

FAQs

What is Immutep Ltd ADR share price today?

Immutep Ltd ADR (IMMP) share price today is $2.08

Can Indians buy Immutep Ltd ADR shares?

Yes, Indians can buy shares of Immutep Ltd ADR (IMMP) on Vested. To buy Immutep Ltd ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IMMP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Immutep Ltd ADR be purchased?

Yes, you can purchase fractional shares of Immutep Ltd ADR (IMMP) via the Vested app. You can start investing in Immutep Ltd ADR (IMMP) with a minimum investment of $1.

How to invest in Immutep Ltd ADR shares from India?

You can invest in shares of Immutep Ltd ADR (IMMP) via Vested in three simple steps:

  • Click on Sign Up or Invest in IMMP stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Immutep Ltd ADR shares
What is Immutep Ltd ADR 52-week high and low stock price?

The 52-week high price of Immutep Ltd ADR (IMMP) is $3.33. The 52-week low price of Immutep Ltd ADR (IMMP) is $1.66.

What is Immutep Ltd ADR price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Immutep Ltd ADR (IMMP) is

What is Immutep Ltd ADR price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Immutep Ltd ADR (IMMP) is 2.63

What is Immutep Ltd ADR dividend yield?

The dividend yield of Immutep Ltd ADR (IMMP) is 0.00%

What is the Market Cap of Immutep Ltd ADR?

The market capitalization of Immutep Ltd ADR (IMMP) is $338.25M

What is Immutep Ltd ADR’s stock symbol?

The stock symbol (or ticker) of Immutep Ltd ADR is IMMP

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top